Page last updated: 2024-10-27

fexofenadine and Breast Cancer

fexofenadine has been researched along with Breast Cancer in 2 studies

fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.

Research Excerpts

ExcerptRelevanceReference
"Paclitaxel (PTX) is one of the most important breast cancer treatment drugs."7.76[Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma]. ( Eguchi, H; Kogure, Y; Komatsubara, K; Matsuhisa, T; Miyoshi, K, 2010)
" Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors."5.48Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018)
"Paclitaxel (PTX) is one of the most important breast cancer treatment drugs."3.76[Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma]. ( Eguchi, H; Kogure, Y; Komatsubara, K; Matsuhisa, T; Miyoshi, K, 2010)
" Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors."1.48Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys. ( Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Karibe, T1
Imaoka, T1
Abe, K1
Ando, O1
Komatsubara, K1
Miyoshi, K1
Kogure, Y1
Matsuhisa, T1
Eguchi, H1

Other Studies

2 other studies available for fexofenadine and Breast Cancer

ArticleYear
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
    Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Mem

2018
[Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Fe

2010